These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38664697)

  • 1. Synergistic effect of human uterine cervical mesenchymal stem cell secretome and paclitaxel on triple negative breast cancer.
    Eiro N; Fraile M; Escudero-Cernuda S; Sendon-Lago J; Gonzalez LO; Fernandez-Sánchez ML; Vizoso FJ
    Stem Cell Res Ther; 2024 Apr; 15(1):121. PubMed ID: 38664697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
    Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
    Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advancing targeted combination chemotherapy in triple negative breast cancer: nucleolin aptamer-mediated controlled drug release.
    Ma Y; Xie D; Chen Z; Shen X; Wu X; Ding F; Ding S; Pan Y; Li F; Lu A; Zhang G
    J Transl Med; 2024 Jul; 22(1):604. PubMed ID: 38951906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adipose derived mesenchymal stem cell secretome formulation as a biotherapeutic to inhibit growth of drug resistant triple negative breast cancer.
    Nadesh R; Menon KN; Biswas L; Mony U; Subramania Iyer K; Vijayaraghavan S; Nambiar A; Nair S
    Sci Rep; 2021 Dec; 11(1):23435. PubMed ID: 34873206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic Anti-Tumor Effect of Toosendanin and Paclitaxel on Triple-Negative Breast Cancer via Regulating ADORA2A-EMT Related Signaling.
    Zhang J; Xu HX; Wu YL; Cho WCS; Xian YF; Lin ZX
    Adv Biol (Weinh); 2023 Aug; 7(8):e2300062. PubMed ID: 37401656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
    Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
    Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
    Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
    Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low Dose of Paclitaxel Combined with XAV939 Attenuates Metastasis, Angiogenesis and Growth in Breast Cancer by Suppressing Wnt Signaling.
    Shetti D; Zhang B; Fan C; Mo C; Lee BH; Wei K
    Cells; 2019 Aug; 8(8):. PubMed ID: 31416135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.
    Burnett JP; Lim G; Li Y; Shah RB; Lim R; Paholak HJ; McDermott SP; Sun L; Tsume Y; Bai S; Wicha MS; Sun D; Zhang T
    Cancer Lett; 2017 May; 394():52-64. PubMed ID: 28254410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential therapeutic effect of the secretome from human uterine cervical stem cells against both cancer and stromal cells compared with adipose tissue stem cells.
    Eiró N; Sendon-Lago J; Seoane S; Bermúdez MA; Lamelas ML; Garcia-Caballero T; Schneider J; Perez-Fernandez R; Vizoso FJ
    Oncotarget; 2014 Nov; 5(21):10692-708. PubMed ID: 25296979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.
    Desroys du Roure P; Lajoie L; Mallavialle A; Alcaraz LB; Mansouri H; Fenou L; Garambois V; Rubio L; David T; Coenon L; Boissière-Michot F; Chateau MC; Ngo G; Jarlier M; Villalba M; Martineau P; Laurent-Matha V; Roger P; Guiu S; Chardès T; Gros L; Liaudet-Coopman E
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38290768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
    Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
    Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An in vitro study on the reversal of epithelial to mesenchymal transition by brusatol and its synergistic properties in triple-negative breast cancer cells.
    Chandrasekaran J; Balasubramaniam J; Sellamuthu A; Ravi A
    J Pharm Pharmacol; 2021 Apr; 73(6):749-757. PubMed ID: 33769483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The GEF-H1/PKD3 signaling pathway promotes the maintenance of triple-negative breast cancer stem cells.
    Lieb WS; Lungu C; Tamas R; Berreth H; Rathert P; Storz P; Olayioye MA; Hausser A
    Int J Cancer; 2020 Jun; 146(12):3423-3434. PubMed ID: 31745977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PRKCQ inhibition enhances chemosensitivity of triple-negative breast cancer by regulating Bim.
    Byerly JH; Port ER; Irie HY
    Breast Cancer Res; 2020 Jun; 22(1):72. PubMed ID: 32600444
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Sendon-Lago J; Seoane S; Saleh F; Garcia-Caballero L; Arias ME; Eiro N; Macia M; Vizoso FJ; Perez-Fernandez R; Schneider J
    Cancer Genomics Proteomics; 2022; 19(5):570-575. PubMed ID: 35985689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting claudin-4 enhances chemosensitivity in breast cancer.
    Luo Y; Kishi S; Sasaki T; Ohmori H; Fujiwara-Tani R; Mori S; Goto K; Nishiguchi Y; Mori T; Kawahara I; Kondoh M; Kuniyasu H
    Cancer Sci; 2020 May; 111(5):1840-1850. PubMed ID: 32086991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer.
    Arango NP; Yuca E; Zhao M; Evans KW; Scott S; Kim C; Gonzalez-Angulo AM; Janku F; Ueno NT; Tripathy D; Akcakanat A; Naing A; Meric-Bernstam F
    Breast Cancer Res; 2017 Aug; 19(1):93. PubMed ID: 28810913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC).
    Cordani N; Lisini D; Coccè V; Paglia G; Meanti R; Cerrito MG; Tettamanti P; Bonaffini L; Paino F; Alessandri G; Marcianti A; Giannì A; Villa C; Mauri M; Mologni L; Torsello A; Pessina A; Cazzaniga ME
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.